Kenvue Shares to Be Delisted Monday After Kimberly-Clark Deal
Kenvue faces stock market delisting Monday morning following its acquisition agreement with Kimberly-Clark, ending its run as an independent public company.
Kenvue, the consumer health spinoff best known for brands like Tylenol and Neutrogena, is set to be removed from public stock exchanges before Monday's opening bell, according to a report from SeekingAlpha. The delisting marks the end of Kenvue's brief tenure as a standalone publicly traded company following its acquisition deal with Kimberly-Clark.
The move signals a significant consolidation in the consumer goods sector, with Kimberly-Clark — the household products giant behind brands such as Kleenex and Huggies — absorbing Kenvue into its portfolio. The deal underscores a broader trend of large consumer staples companies seeking scale and diversification as the sector faces persistent cost pressures and shifting consumer demand.
Read more Global Payments Stock Surges on CD&R Takeover Report →
Kenvue was originally spun off from Johnson & Johnson in 2023 in one of the largest healthcare consumer IPOs in recent memory. Its rapid transition from IPO to delisting reflects how quickly the competitive and financial landscape can shift for consumer health companies navigating post-spinoff independence.
For shareholders, the delisting means trading in Kenvue's common stock will cease as of Monday's market open, with investors needing to assess the terms of the Kimberly-Clark transaction to understand how their holdings will be treated going forward. The deal's completion represents a notable endpoint for a company that had only recently begun trading as its own entity.
Continue reading at SeekingAlpha.
